Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
about
Towards personalised therapy for von Willebrand disease: a future role for recombinant productsHuman plasma-derived FVIII/VWD concentrate (Biostate): a review of experimental and clinical pharmacokinetic, efficacy and safety dataThe diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.Successful aortic aneurysm repair in a woman with severe von Willebrand (type 3) disease.Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand diseaseIncreased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia.A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).Treatment of von Willebrand disease with FVIII/VWF concentratesInteraction between VWF and FVIII in treating VWD.Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.Effect of general and epidural anesthesia on hemostasis and fibrinolysis in hepatic patients.Repeated infusions of VWF/FVIII concentrate: impact of VWF:FVIII ratio on FVIII trough and peak levels in a rabbit model.Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer.
P2860
Q26748376-5D27C3E7-BCCD-40A4-8D1B-5ADAA3C227F7Q26750402-66B4216E-3CAD-4B9A-8395-6054ACDA9AB6Q34816051-EA6C345B-124C-4D67-A2E7-44E3CDCAE6FFQ35563446-29563EF1-A961-4409-9C24-061A448BEE60Q36193201-4618B71B-412E-44C4-A9EA-E565BF79BBF5Q36914340-129DF8A8-7659-48EA-844B-23CA1FEB26A5Q37124978-75AB8F7F-4225-48E6-AF2F-C83A35759D24Q37357218-0ED89433-92DA-4C79-8CFD-FE2CAF10798EQ37635167-B016D25E-7EEA-48E2-AD32-DB4F6439B0AAQ37645977-C2E72F18-BB8C-43D7-A85D-6CF26328D02EQ37916747-BDEC676D-566F-46C6-B532-B1FFAC7711D5Q38326080-78130D50-E7F2-4959-8485-84527ABB8A5EQ38687056-E42C6BFC-E529-4973-99BF-8A05D8CCF968Q40110462-8B14A56D-BFC9-41F9-BF8A-B26C4E4BEAB0Q42878309-4C3BF750-CB21-464C-8982-4252A32C2AA3Q45871507-27E9B635-6395-4CDE-8138-FDF7C1AF4DFCQ48518084-DC465AB2-15BF-42F4-B7CB-ECE5B3909698
P2860
Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Comparative analysis and class ...... s with von Willebrand disease.
@ast
Comparative analysis and class ...... s with von Willebrand disease.
@en
type
label
Comparative analysis and class ...... s with von Willebrand disease.
@ast
Comparative analysis and class ...... s with von Willebrand disease.
@en
prefLabel
Comparative analysis and class ...... s with von Willebrand disease.
@ast
Comparative analysis and class ...... s with von Willebrand disease.
@en
P356
P1476
Comparative analysis and class ...... s with von Willebrand disease.
@en
P2093
Heinz-Georg Müller
Hubert J Metzner
P304
P356
10.1055/S-2006-949668
P50
P577
2006-09-01T00:00:00Z